Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 1.07%38.860.9%$1256.71m
JNJJohnson & Johnson 0.40%148.990.7%$900.02m
MRKMerck & Co., Inc. 0.65%82.170.6%$646.92m
ABBVAbbVie, Inc. 0.23%93.461.9%$601.08m
BMYBristol-Myers Squibb Co. 4.44%62.341.0%$594.59m
AZNAstraZeneca Plc 0.16%56.041.2%$577.62m
LLYEli Lilly & Co. 0.49%155.091.1%$448.88m
NVSNovartis AG 0.36%83.720.2%$138.55m
GSKGlaxoSmithKline Plc -0.49%41.010.2%$134.76m
OPKOPKO Health, Inc. 1.65%5.5411.2%$131.32m
MISTMilestone Pharmaceuticals, Inc. 0.89%9.040.0%$122.85m
RGENRepligen Corp. 0.49%156.657.1%$70.27m
NVONovo Nordisk A/S -1.71%63.980.1%$65.27m
PRNBPrincipia Biopharma, Inc. -1.21%88.980.0%$59.90m
IMRNImmuron Ltd. 3.29%11.310.0%$54.57m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.